{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-025855","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2022-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.864089+00:00","generated_at":"2026-06-23T05:51:22.028403+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"Cardiff Oncology posts updated corporate presentation on onvansertib clinical pipeline","bullets":["Presentation covers onvansertib as a PLK1 inhibitor with potential in KRAS-mutated cancers.","Highlights ongoing Phase 1b/2 trials in mCRC, mPDAC, TNBC, and SCLC with historical ORR benchmarks.","Includes strategic goals for 2022-2025: demonstration, confirmation, and positioning for registration.","No specific new clinical data or financial guidance announced in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-025855","json":"https://secwatch.observer/filing/0001628280-22-025855.json","markdown":"https://secwatch.observer/filing/0001628280-22-025855.md","text":"https://secwatch.observer/filing/0001628280-22-025855.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022025855/0001628280-22-025855-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022025855/crdf-20221003.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T05:51:22.028403+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}